China SXT Pharmaceuticals, Inc.
SXTC
Analytical Summary
China SXT Pharmaceuticals, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.
11-Year Financial Trajectory
QuarterlyBullish Indicators
- Debt to EquityDebt to Equity is in the top quartile (lower is better)
Bearish Risks
- Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | Q4 FY2026 Mar 31, 2026 20-F ↗ | Q4 FY2025 Mar 31, 2025 20-F ↗ | Q4 FY2024 Mar 31, 2024 20-F ↗ | Q4 FY2023 Mar 31, 2023 20-F ↗ | Q4 FY2022 Mar 31, 2022 20-F ↗ | Q4 FY2021 Mar 31, 2021 20-F ↗ | Q4 FY2020 Mar 31, 2020 20-F ↗ | Q4 FY2019 Mar 31, 2019 20-F ↗ | Q4 FY2018 Mar 31, 2018 20-F ↗ | Q4 FY2017 Mar 31, 2017 20-F ↗ | Q4 FY2016 Mar 31, 2016 20-F ↗ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt to Equity (x) |
0.03x
Excellent
↓
Excellent
Declining
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-94%)
|
0.10x
Excellent
↑
Excellent
Improving
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-84%)
|
0.08x
Excellent
↑
Excellent
Improving
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-87%)
|
0.02x
Excellent
↑
Excellent
Improving
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-97%)
|
0.00x
Excellent
↓
Excellent
Declining
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-100%)
|
0.00x
Excellent
↓
Excellent
Declining
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-100%)
|
0.01x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-99%)
|
0.01x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-99%)
|
— | — | — |
| Net Debt (USD) | $-27.18M | $-16.59M | $-10.95M | $-17.08M | $11.40K | $-13.32M | $-7.21M | $-9.06M | $-560.25K | $-65.57K | $-11.44K |
| Metric | Q4 FY2026 Mar 31, 2026 20-F ↗ | Q4 FY2025 Mar 31, 2025 20-F ↗ | Q4 FY2024 Mar 31, 2024 20-F ↗ | Q4 FY2023 Mar 31, 2023 20-F ↗ | Q4 FY2022 Mar 31, 2022 20-F ↗ | Q4 FY2021 Mar 31, 2021 20-F ↗ | Q4 FY2020 Mar 31, 2020 20-F ↗ | Q4 FY2019 Mar 31, 2019 20-F ↗ | Q4 FY2018 Mar 31, 2018 20-F ↗ | Q4 FY2017 Mar 31, 2017 20-F ↗ | Q4 FY2016 Mar 31, 2016 20-F ↗ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Working Capital (USD) | $30.16M | $15.28M | $5.33M | $5.02M | $5.33M | $4.65M | $7.37M | $9.27M | $1.73M | — | — |
| LT Debt (USD) | $644.39K | $807.23K | $631.51K | $117.86K | — | $6.29K | $36.51K | $41.71K | — | — | — |
| Total Equity (USD) | $29.71M | $15.44M | $13.93M | $14.69M | $16.42M | $15.96M | $9.40M | $11.11M | $3.29M | $1.85M | $742.77K |
Secondary lens
Benchmark Lens
Compare SXTC against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare SXTC against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for SXTC
Debt to Equity is in the top quartile (lower is better)
Return on Common Equity (%) is in the bottom quartile
Percentile Rankings
How SXTC compares to all companies
Peer Comparison
SXTC vs similar peers
Compare SXTC with peers
Stack SXTC against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 11 years · 11 quarters